February 23, 2024
Loading...
You are here:  Home  >  Banking & Finance  >  Tri-County Public Companies  -  Page 201
Latest

Freska buys Oceanside avocado packing plant

By   /  Thursday, December 17th, 2015  /  Agribusiness, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Freska buys Oceanside avocado packing plant

Oxnard-based Freska Produce International has purchased an avocado packer, Harvest Time Produce of Oceanside, the company announced in a news release Dec. 17. The move by Freska, which already has a Mexican avocado program, will allow the company known for mangoes to use the Oceanside packing plant to become a year-round provider of avocados. Terms Read More →

Latest

Amgen increases dividend to $1 per share

By   /  Tuesday, December 15th, 2015  /  Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Amgen increases dividend to $1 per share

Amgen increased its yearly dividend 27 percent this year to $1 per share. Previously, the dividend had been 79 cents per share for the Thousand Oaks-based biotech giant. Shares jumped after news of the 27-cent dividend broke. The announcement was made just after the markets closed at 1:11 p.m. Amgen closed the trading day up Read More →

Latest

Ceres plans to raise $6.7 million through public stock offering Dec. 17

By   /  Tuesday, December 15th, 2015  /  Agribusiness, Latest news, Tri-County Public Companies  /  Comments Off on Ceres plans to raise $6.7 million through public stock offering Dec. 17

Ceres, a Thousand Oaks-based agriculture-biotechnology company, priced shares at 40 cents each on Dec. 15 for its follow-on public offering on Dec. 17. Ceres plans to raise $6.7 million through the offering, which will be comprised of 600,000 shares of common stock, 6,460 shares of preferred stock convertible into 16,150,000 shares of common stock, and Read More →

Latest

Amgen reacquires rights to sell 3 drugs worldwide

By   /  Monday, December 14th, 2015  /  Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Amgen reacquires rights to sell 3 drugs worldwide

Amgen reacquired all rights to sell three drugs worldwide on Dec. 14. The Thousand Oaks-based biotech giant said it reacquired the rights to Prolia, Vectibix and Xgeva in 48 ccountries from British pharmaceutical company GlaxoSmithKline. The agreement includes large countries like Australia, China and Brazil. Prolia is designed to raise bone density in people with Read More →

Latest

CalAmp makes $113 million offer to acquire LoJack

By   /  Thursday, December 10th, 2015  /  Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on CalAmp makes $113 million offer to acquire LoJack

Oxnard-based CalAmp made a $113 million offer Dec. 10 to acquire LoJack, the maker of theft recovery systems for cars, trucks and construction equipment. The offer of $5.50 a share is a 58 percent premium to LoJack’s closing price on Dec. 9 and a 24 percent premium to LoJack’s 52-week high. CalAmp has had friendly Read More →

Latest

Novartis biosimilar works as well as Amgen’s Neulasta

By   /  Monday, December 7th, 2015  /  Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Novartis biosimilar works as well as Amgen’s Neulasta

Swiss pharmaceutical Novartis announced Monday that a copycat version of Amgen’s Neulasta works just as well to prevent a condition that can lead to infection in women with breast cancer. Neulasta stimulates white blood cell production in the body, which helps the body fight cancer. Novartis’ new drug is part of a new class of Read More →

Latest

Amgen seeks European OK of biosimilar drug, partners with Merck on studies

By   /  Friday, December 4th, 2015  /  East Ventura County, Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Amgen seeks European OK of biosimilar drug, partners with Merck on studies

Amgen announced two developments Dec. 4 that should help the Thousand Oaks-based biotech giant compete. Amgen said it is seeking approval from the European Medicines Agency for ABP 501, a biosimilar drug similar to Humira. Amgen also announced a partnership with New Jersey-based pharmaceutical Merck to partner in a non-Hodgkins lymphoma study using drugs from Read More →